Retatrutide, Tirzepatide and Semaglutide are three peptides that appear regularly in metabolic and endocrine research. All three interact with incretin-related pathways, but they differ in the number of receptors they target and in the type of research questions they are used to explore.
This article provides a clear, research-only comparison of the three compounds. It is written for laboratory teams who want a practical overview of the main differences, common study areas, and points to consider when sourcing these materials.
Why These Three Peptides Are Compared
In recent years, research interest in multi-receptor agonists has increased. Semaglutide, Tirzepatide and Retatrutide are often discussed together because they represent different stages of development within the same broad research area.
Semaglutide acts on one receptor. Tirzepatide acts on two. Retatrutide acts on three. This progression makes them useful for comparative studies that examine how receptor breadth influences experimental outcomes in metabolic models.
Quick Comparison Table
The table below summarises the key differences relevant to laboratory research teams:
| Feature | Semaglutide | Tirzepatide | Retatrutide |
| Receptor activity | GLP-1 only (single agonist) | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + Glucagon (triple agonist) |
| Primary research focus | Appetite regulation, glucose metabolism, satiety signalling | Combined incretin signalling, energy balance, dual-pathway models | Multi-receptor metabolic signalling, energy expenditure models |
| Research maturity | Longer research history; extensive published laboratory data | Well-characterised dual agonist with growing preclinical literature | Newer compound; expanding preclinical and structural studies |
| Typical laboratory use | Reference single-agonist compound | Comparative dual-agonist studies | Broader receptor-profile investigations |
This overview is intended only as a research orientation tool. Experimental design should always be guided by the specific aims of the study and the available scientific literature.
Semaglutide – Single Receptor (GLP-1)
Semaglutide is a long-acting GLP-1 receptor agonist. In laboratory and preclinical research, it is one of the most widely examined compounds in its class.
Researchers typically study Semaglutide in relation to:
- Appetite regulation pathways
- Glucose metabolism
- Satiety signalling
- Energy intake models
Because it targets only the GLP-1 receptor, Semaglutide is often used as a reference compound when comparing newer dual or triple agonists. Its longer research history means a larger body of published laboratory data is available for review.
Zentra Labs supplies research-grade Semaglutide for laboratory use. View the product page:
Tirzepatide – Dual Receptor (GLP-1 + GIP)
Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor. This dual activity is the main reason it is studied alongside Semaglutide.
In research settings, Tirzepatide is commonly examined in models related to:
- Combined incretin signalling
- Metabolic pathway interactions
- Energy balance research
- Comparative studies against single GLP-1 agonists
Pharmacological characterisation has shown that Tirzepatide engages the GIP receptor with relatively high affinity while also activating the GLP-1 receptor, giving researchers a tool to explore dual incretin effects in controlled laboratory systems.
Zentra Labs supplies research-grade Tirzepatide for laboratory use. View the product page:
Retatrutide – Triple Receptor (GLP-1 + GIP + Glucagon)
Retatrutide extends the multi-receptor concept further by acting as a triple agonist at the GLP-1, GIP and glucagon receptors. Preclinical characterisation has described its balanced activity across these three receptors (Coskun et al., related structural and pharmacological studies).
In laboratory research, Retatrutide is of interest for studies involving:
- Multi-receptor metabolic signalling
- Energy expenditure and metabolic pathway models
- Comparative work against dual and single agonists
- Receptor interaction and signalling mechanism investigations
Because it engages an additional receptor pathway compared with Tirzepatide, Retatrutide offers research teams a broader profile for examining how receptor breadth influences experimental outcomes.
Zentra Labs supplies research-grade Retatrutide for laboratory use. View the product page:
What Researchers Typically Consider When Sourcing These Materials
When selecting multi-receptor research peptides, laboratory teams often look for:
- Clear research-use-only designation on the product page and packaging
- Batch-specific documentation or Certificates of Analysis (COA)
- Independent laboratory testing where available
- Clear storage and handling guidance
- Reliable shipping practices, especially for temperature-sensitive materials
Independent laboratory testing and batch-specific documentation can help researchers verify the identity and analytical characteristics of materials used in experimental work. It is good practice to review the available documentation for the specific batch being ordered rather than relying on general product claims.
Storage and Handling Notes
Most research peptides in this class are supplied as lyophilised powders. General laboratory practice often includes storing unopened vials in a cool, dry place away from light, reconstituting according to institutional protocols, and avoiding unnecessary freeze-thaw cycles once in solution.
Storage and reconstitution requirements can vary by peptide and by batch. Researchers should always refer to the product-specific or batch-specific documentation supplied with the material, and follow their own laboratory protocols, rather than relying solely on general guidance.
Research Use Only
All three compounds discussed in this article are intended strictly for laboratory research and analytical purposes. They are not intended for human consumption, medical use, therapeutic use, diagnostic use, or veterinary use.
Researchers are responsible for ensuring that their work complies with all applicable institutional and regulatory requirements.
Final Notes
Semaglutide, Tirzepatide and Retatrutide each offer a different receptor profile for metabolic and endocrine research. Semaglutide provides a well-studied single-agonist reference. Tirzepatide adds GIP activity. Retatrutide extends the profile further by including glucagon receptor activity.
Understanding these differences helps research teams select the most appropriate compound for their specific experimental questions. When sourcing any of these materials, prioritising batch-specific documentation, independent laboratory testing where available, and clear research-use-only status supports better experimental control.
Zentra Labs is a UK-based supplier of research peptides for laboratory use. Batch-specific documentation is available to support research teams reviewing the materials they order. Explore the full range of research compounds in the shop.
